Rubitecan Chemical Properties

Melting point:

182-186°C

alpha 

D23 +27° (c = 0.2 in CH3OH-CHCl3, 1:4)

Boiling point:

816.3±65.0 °C(Predicted)

Density 

1.63

Flash point:

106℃

storage temp. 

Sealed in dry,Room Temperature

solubility 

DMSO, Chloroform, Methanol

form 

Solid

pka

11.16±0.20(Predicted)

color 

Yellow

Merck 

14,8288

CAS DataBase Reference

91421-42-0(CAS DataBase Reference)

Safety Information

Safety Statements 

24/25

WGK Germany 

3

RTECS 

UQ0493300

HS Code 

29399990

Rubitecan Usage And Synthesis

Description

Rubitecan, marketed by Supergen as Orathecin, is a promising oral treatment for solid melanoma, prostate, breast, ovarian, and other cancers, as well as leukemia. It is a derivative of camptothecin, a topoisomerase inhibitor known from Chinese Traditional Medicine. It selectively targets the critical S-stage of cellular reproduction – particularly in acidic environments, as in many cancer cells – relaxing DNA supercoiling and generating lethal breaks in the DNA. Due to insolubility, its biological delivery mechanism is not yet effective, and it has not been approved for clinical use.

Reference

https://www.sciencedirect.com/topics/medicine-and-dentistry/rubitecan
https://en.wikipedia.org/wiki/Rubitecan
https://en.wikipedia.org/wiki/Topoisomerase_inhibitor
https://en.wikipedia.org/wiki/Camptothecin#cite_note-Y.Pommier_2003-14
https://www.ncbi.nlm.nih.gov/pubmed/1995300

Description

Rubitecan is a DNA topoisomerase I inhibitor. It inhibits DNA topoisomerase I and increases the fraction of supercoiled DNA in a cell-free assay in a concentration-dependent manner. Rubitecan inhibits the growth of A121 ovarian and H460 lung cancer cells (IC₅₀s = 4 and 2 nM, respectively). It also inhibits the growth of doxorubicin-susceptible and -resistant MCF-7 breast cancer cells (IC₅₀s = 2 and 3 nM, respectively). Rubitecan (4 mg/kg twice per week) reduces tumor growth in a U937 leukemia mouse xenograft model.

Chemical Properties

Yellow Amorphous Powder

Uses

Semisynthetic camptothecin which inhibits DNA topoisomerase I. Prodrug of 9-aminocamptothecin. Antineoplastic.

Definition

ChEBI: A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.

Rubitecan(91421-42-0)Related Product Information

• (+)-Camptothecin
• 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4-hydroxy-9-methoxy-, (4S)-
• SN-38-D3
• 7-Ethyl-20(R)-camptothecin
• daurisoline
• 2-[2-(Methylamino)benzoyl]-3,4-dihydro-β-carboline-1(2H)-one
• L-Hyoscyamine
• Xanthiazone
• VERATRINE
• veratramine
• VERATRIDINE
• menisdaurin
• Daurinoline
• Xanthiside
• 9-Aminocamptothecin
• 20R-Camptothecin
• Camptothecin
• 7-ETHYL-10-HYDROXYCAMPTOTHECIN,98%